The BCR-ABL1 targeting TK inhibitor (TKI) imatinib was found to downregulate IL-6 and IL-8 release in primary CML cells in vitro [93]. This evidence concerns the gene IL6 and chronic myelogenous leukemia, BCR-ABL1 positive.